サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1628899

がん胎児性抗原の世界市場：性別・用途別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2024年～2032年)

Carcinoembryonic Antigen Market, By Gender, By Application, By End-user, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032

出版日
ページ情報
英文 316 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
がん胎児性抗原の世界市場：性別・用途別・エンドユーザー別・国別・地域別 - 産業分析、市場規模・シェア、将来予測 (2024年～2032年)
出版日: 2024年12月04日
発行: AnalystView Market Insights
ページ情報: 英文 316 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

レポートハイライト

がん胎児性抗原の市場規模は2023年に22億1,550万米ドルとなり、2024年から2032年にかけてCAGR 6.50%で拡大

がん胎児性抗原の市場力学

がん罹患率の上昇

がんの罹患率が上昇していることから、がん胎児性抗原 () 市場が将来的に活性化すると予測されています。異常細胞の無秩序な開発と拡散は、がんの特徴です。がんは、高齢化、遺伝的素因、環境汚染物質、ライフスタイルの選択の結果として一般的になりつつあります。腫瘍マーカーであるがん胎児性抗原 (CEA：カルチノエンブリオニック抗原) は、がんの経過や治療効果を追跡するために使用されます。例えば、米国に本部を置く政府間機関である世界保健機関 (WHO) は2024年2月、2050年にはがんの新規症例が約3,500万件発生すると予想され、2022年の予測2,000万件から77%増加すると述べています。このように、がん胎児性抗原市場は、がん罹患率の増加により拡大しています。

がん胎児性抗原市場：主な考察

当社のリサーチアナリストが共有した分析によると、世界のがん胎児性抗原市場は、予測期間 (2024～2032年) に約6.50%のCAGRで毎年成長すると予測されています。

性別では、男性カテゴリは2023年に最大の市場シェアを示すと予測されました。

用途別では、消化器がんが2023年の主要セグメントでした。

地域別では、2023年に北米が主要な収益源となりました。

がん胎児性抗原市場：セグメンテーション分析

世界のがん胎児性抗原市場は、性別、用途、エンドユーザー、地域に基づいてセグメント化されます。

用途別では、肺がん、消化器がん (大腸がん、食道がん、肝臓がん、膵臓がん、胃がん、肛門がん、胆のうがん)、乳がん、卵巣がん、前立腺がん、甲状腺がんに分けられます。2023年、市場は消化器がんカテゴリーが支配的でした。世界的に、結腸がん、胃がん、膵臓がんは腸がんの中でも最も一般的なタイプです。これらの疾患は有病率が高く、攻撃的な性質を持つため、効率的な診断・モニタリング法の必要性が高まっており、CEAはこれらの疾患の重要なバイオマーカーとして機能しています。さらに、リスクは加齢とともに増加するため、特に先進地域における人口の高齢化は、消化管悪性腫瘍の有病率の増加に寄与しています。CEA検査に対する需要は、この人口動向によってさらに高まり、消化器がん分野の関連性をさらに確固たるものにしています。

がん胎児性抗原市場は、病院、腫瘍クリニック、診断研究所、研究センター、学術機関などのエンドユーザーセグメントに分けられます。2023年の病院セグメントの売上は。がんの診断、治療、サーベイランスの主な場所は病院で、そこではCEA検査が一般的に使用されています。CEA検査の病院での使用は、世界のがん罹患率の上昇に伴うモニタリングおよび診断ツールに対する需要の高まりの結果として増加しています。CEA検査の正確で効果的な使用は、病院が訓練を受けたスタッフや最先端の診断ツールを頻繁に利用できることによってさらに促進されます。病院での日常的なモニタリングとがん患者の早期発見に重点を置いていることが、このセグメントの成長に寄与しています。

がん胎児性抗原市場：地域別分析

地域的には、がん胎児性抗原市場は、北米、ラテンアメリカ、欧州、アジア太平洋、中東およびアフリカの地域で広く普及しています。これらの地域は、ビジネスをもたらす国ごとにさらに分割されます。

北米のがん胎児性抗原市場は、がん罹患率の高さ、洗練された医療システム、多額の研究開発費により、世界的に優位を占めています。がんの早期発見と早期モニタリングが治療の成功に不可欠であることから、この地域の市場は拡大しています。2023年には、北米で新たに190万人ががんと診断されると米国がん協会は予測しています。CEAやその他の腫瘍マーカーは、この高い罹患率により高い需要があります。さらに、アボット・ラボラトリーズやロシュ・ダイアグノスティックスなど、多くの大手診断薬企業が北米に拠点を置いており、この需要の高まりに対応するため、常に製品ラインを開発・拡充しています。

しかし、今後数年間、アジア太平洋地域のがん胎児性抗原市場は、がん罹患率の上昇、医療費の高騰、がんの早期発見に対する意識の高まりなどの要因により、大きく成長すると予想されます。中国、インド、日本は、人口が多く、がんの罹患率が高いため、この拡大の最前線にあります。国際がん研究機関 (IARC) によると、2020年にはアジアが世界のがん患者の約49.3%を占めています。この地域における市場拡大をさらに促進するのは、医療施設を強化し、CEAのような早期診断検査を奨励する政府のプログラムです。

がん胎児性抗原市場：競合情勢

がん胎児性抗原市場は、Quest Diagnostics社、Thermo Fisher Scientific社、Boster Biological Technology社、Abcam Limited社、Creative Diagnostics社、F. Hoffmann-La Roche Ltd社などの大手企業間の熾烈な競争によって牽引されています。これらの企業は、幅広いポートフォリオと強固な販売網を活用しながら、がん胎児性抗原検査の精度と価格を向上させるために研究開発に投資しています。イムノアッセイやポイントオブケア診断の進歩を通じて、新興企業も業界を後押ししています。さらに、技術開発とがんの早期発見とモニタリングの重視の高まりが市場需要を牽引し、既存・新興の両業界に門戸を開いています。例えば、2023年12月、サノフィによりtusamitamab ravtansineの世界的科学開発プロジェクトが中止されます。すでに治療を受けている転移性非扁平上皮非小細胞肺がん (NSCLC) 患者を対象に、ツサミタマブ・ラブタンシンを単剤療法としてドセタキセルと比較評価する第3相CARMEN-LC03試験が、この決定の原因です。

目次

第1章 がん胎児性抗原市場の概要

  • 調査範囲
  • 市場推定期間

第2章 エグゼクティブサマリー

  • 市場内訳
  • 競合考察

第3章 がん胎児性抗原の主な市場動向

  • 市場促進要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 がん胎児性抗原市場：産業分析

  • PEST分析
  • ポーターのファイブフォース分析
  • 市場成長の見通し：マッピング
  • 規制体制の分析

第5章 がん胎児性抗原市場：COVID-19の影響分析

  • COVID-19以前の影響分析
  • COVID-19以後の影響分析

第6章 がん胎児性抗原の市場情勢

  • がん胎児性抗原の市場シェア分析 (2023年)
  • 主要メーカー別の内訳データ
    • 既存企業の分析
    • 新興企業の分析

第7章 がん胎児性抗原市場：性別

  • 概要
    • セグメント別シェア分析：性別
    • 男性
    • 女性

第8章 がん胎児性抗原市場：用途別

  • 概要
    • セグメント別シェア分析：用途別
    • 肺がん
    • 消化器がん
      • 大腸がん
      • 食道がん
      • 肝臓がん
      • 膵臓がん
      • 胃がん
      • 肛門がん
      • 胆嚢がん
    • 乳がん
    • 卵巣がん
    • 前立腺がん
    • 甲状腺がん

第9章 がん胎児性抗原市場：エンドユーザー別

  • 概要
    • セグメント別シェア分析：エンドユーザー別
    • 病院
    • 腫瘍科クリニック
    • 診断検査室
    • 研究センター・学術機関

第10章 がん胎児性抗原市場：地域別

  • イントロダクション
  • 北米
    • 概要
    • 北米の主要メーカー
    • 米国
    • カナダ
  • 欧州
    • 概要
    • 欧州の主要メーカー
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • 英国
    • ロシア
    • オランダ
    • スウェーデン
    • ポーランド
    • その他
  • アジア太平洋 (APAC)
    • 概要
    • アジア太平洋の主要メーカー
    • インド
    • 中国
    • 韓国
    • 日本
    • オーストラリア
    • タイ
    • インドネシア
    • フィリピン
    • その他
  • ラテンアメリカ
    • 概要
    • ラテンアメリカの主要メーカー
    • ブラジル
    • メキシコ
    • アルゼンチン
    • コロンビア
    • その他
  • 中東・アフリカ
    • 概要
    • 中東・アフリカの主要メーカー
    • サウジアラビア
    • アラブ首長国連邦
    • イスラエル
    • トルコ
    • アルジェリア
    • エジプト
    • その他

第11章 主要ベンダー分析：がん胎児性抗原業界

  • 競合ダッシュボード
  • 企業プロファイル
    • Boster Biological Technology
    • Abcam Limited
    • Creative Diagnostics
    • Aviva Systems Biology Corporation
    • AdvaCare Pharma
    • F. Hoffmann-La Roche Ltd.
    • Thermo Fisher Scientific Inc.
    • Omega Diagnostics Ltd.
    • Medix Biochemica
    • RayBiotech, Inc.
    • Diazyme Laboratories Inc.
    • Quest Diagnostics Incorporated
    • Others

第12章 アナリストの全方位展望

目次
Product Code: ANV4432

REPORT HIGHLIGHT

Carcinoembryonic Antigen Market size was valued at USD 2,215.5 Million in 2023, expanding at a CAGR of 6.50% from 2024 to 2032.

The endodermal epithelial cells of the embryo contain carcinoembryonic antigen (CEA). The fluids of the fetus, embryo, and gastrointestinal tract contain a glycoprotein called carcinoembryonic antigen. Carcinoembryonic antigen is also present in trace amounts in the blood, gastrointestinal cells, and colon mucosal cells. Additionally, the test can be used to diagnose and treat cancers like ovarian, lung, liver, colorectal, gastrointestinal, or colon cancers, as well as breast cancer. The market is expected to rise as a result of rising cancer incidence, an ageing population, and increased awareness. Over the past ten years, there has been a notable increase in the yearly number of cancer diagnoses worldwide. Additionally, as life expectancy rises, more people will receive a diagnosis during their lifetime, which will fuel market expansion.

Carcinoembryonic Antigen Market- Market Dynamics

Rising Incidence of Cancer

It is anticipated that the rising cases of cancer will fuel the market for carcinoembryonic antigens in the future. Uncontrolled development and spread of aberrant cells is a hallmark of cancer. Cancer is becoming common as a result of ageing populations, genetic predispositions, environmental pollutants, and lifestyle choices. The tumour marker carcinoembryonic antigen (CEA) is used to track the course of cancer and the efficacy of treatment. For instance, the World Health Organization (WHO), an intergovernmental agency based in the United States, stated in February 2024 that around 35 million new cases of cancer are expected to occur in 2050, a 77% increase from the 20 million cases forecast in 2022. Thus, the carcinoembryonic antigen market is expanding due to the increase in cancer incidence.

Carcinoembryonic Antigen Market- Key Insights

As per the analysis shared by our research analyst, the global Carcinoembryonic Antigen Market is estimated to grow annually at a CAGR of around 6.50% over the forecast period (2024-2032)

Based on gender segmentation, the male category was predicted to show the maximum market share in the year 2023

Based on application segmentation, the gastrointestinal cancer was the leading segment in 2023

On the basis of region, North America was the leading revenue generator in 2023

Carcinoembryonic Antigen Market- Segmentation Analysis:

The Global Carcinoembryonic Antigen Market is segmented on the basis of Gender, Application, End-user, and Region.

By application, the market is divided into Lung cancer, Gastrointestinal cancer (Colorectal cancer, Esophageal cancer, Liver cancer, Pancreatic cancer, Stomach cancer, Anal cancer, Gall bladder cancer), Breast cancer, Ovarian cancer, Prostate cancer, and Thyroid cancer. In 2023, the market was dominated by the gastrointestinal cancer category. Globally, colon, stomach, and pancreatic cancers are among the most common types of intestinal cancers. The need for efficient diagnostic and monitoring methods is fueled by their high prevalence and aggressive nature, with CEA acting as a crucial biomarker for these disorders. Furthermore, because the risk increases with age, the ageing population-especially in developed regions-contributes to the increased prevalence of gastrointestinal malignancies. The demand for CEA testing is further increased by this demographic trend, which further solidifies the gastrointestinal cancer segment's relevance.

The market for carcinoembryonic antigens is divided into end-user segments, including Hospitals, Oncology clinics, Diagnostic laboratories, Research centres and academic institutes. Revenue for the hospitals' segment in 2023 was. The main locations for cancer diagnosis, treatment, and surveillance are hospitals, where CEA testing is commonly used. Hospital usage of CEA tests is increasing as a result of the increased demand for monitoring and diagnostic tools due to the rising incidence of cancer worldwide. The accurate and effective use of CEA testing is further facilitated by hospitals' frequent access to trained staff and cutting-edge diagnostic tools. The focus on routine hospital monitoring and early detection of cancer patients contributes to the segment's growth.

Carcinoembryonic Antigen Market- Geographical Insights

Geographically, the Carcinoembryonic Antigen Market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

The market for carcinoembryonic antigen in North America is dominated worldwide due to the region's high cancer incidence, sophisticated healthcare system, and significant R&D expenditures. Due to the fact that early cancer identification and monitoring are essential for successful treatment, the market in this region is growing. In 2023, the American Cancer Society projected that 1.9 million new cases of cancer will be diagnosed in North America. CEA and other tumour markers are in high demand due to this high incidence rate. Furthermore, a number of major diagnostics companies, such as Abbott Laboratories and Roche Diagnostics, are based in North America and are constantly developing and broadening their product lines to meet this rising demand.

However, over the upcoming years, the carcinoembryonic antigen market in the Asia-Pacific region is expected to rise significantly due to factors such as rising cancer prevalence, rising healthcare costs, and increased awareness of early cancer detection. China, India, and Japan are at the forefront of this expansion because of their sizable populations and greater rates of cancer. In 2020, Asia accounted for around 49.3% of all cancer cases worldwide, as per the International Agency for Research on Cancer (IARC). Further driving market expansion in the area are government programs to enhance healthcare facilities and encourage early diagnostic testing, such as CEA.

Carcinoembryonic Antigen Market- Competitive Landscape:

The carcinoembryonic antigen market is driven by fierce competition between major firms, including Quest Diagnostics, Thermo Fisher Scientific Inc., Boster Biological Technology, Abcam Limited, Creative Diagnostics, and F. Hoffmann-La Roche Ltd, among others. These companies invest in R&D to improve the precision and affordability of carcinoembryonic antigen tests while utilizing their broad portfolios and robust distribution networks. Through advancements in immunoassays and point-of-care diagnostics, emerging businesses are also boosting the industry. Furthermore, technical developments and the growing emphasis on early cancer detection and monitoring are driving market demand and opening doors for both established and up-and-coming competitors. For instance, in December 2023, the global scientific development project for tusamitamab ravtansine is being halted by Sanofi. The Phase 3 CARMEN-LC03 trial, which evaluates tusamitamab ravtansine as a monotherapy in comparison to docetaxel in patients with metastatic non-squamous non-small cellular lung cancer (NSCLC) who have already received treatment, is the source of this decision.

Recent Developments:

April 2024: The renowned AI TechBio business and precision medicine pioneer Caris DiscoveryTM, the research arm of Caris Life Sciences(R) (Caris), announced a long-term strategic partnership with Merck KGaA, headquartered in Darmstadt, Germany. In the United States and Canada, Merck KGaA, which operates its healthcare business under the name EMD Serono, will partner with Caris DiscoveryTM to accelerate the search for and development of superior antibody-drug conjugates (ADC) for cancer patients.

March 2024: The FDA designated A2 Biotherapeutics Inc. as an orphan medication for A2B530, a new cell therapy designed to treat colorectal cancer in patients with germline heterozygous HLA-A02 positivity whose tumours express CEA but no longer express HLA-A02. This designation encourages the development of the medication. It provides incentives for progress in the treatment of colorectal cancer by highlighting its potential to address a major unmet need in this particular patient population.

July 2023: To determine the hepatitis C virus (HCV) antigen and antibody status simultaneously and independently from a single human plasma or blood sample, Roche Diagnostics India introduced the Elecsys HCV Duo, the country's first completely automated immunoassay. This innovative diagnostic technology simplifies the procedure for medical professionals and improves patient outcomes, representing a major advancement in HCV identification.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Boster Biological Technology
  • Abcam Limited
  • Creative Diagnostics
  • Aviva Systems Biology Corporation
  • AdvaCare Pharma
  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Omega Diagnostics Ltd.
  • Medix Biochemica
  • RayBiotech, Inc.
  • Diazyme Laboratories Inc.
  • Quest Diagnostics Incorporated
  • Others

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY GENDER- MARKET ANALYSIS, 2019 - 2032

  • Male
  • Female

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Lung cancer
  • Gastrointestinal cancer
  • Colorectal cancer
  • Esophageal cancer
  • Liver cancer
  • Pancreatic cancer
  • Stomach cancer
  • Anal cancer
  • Gall bladder cancer
  • Breast cancer
  • Ovarian cancer
  • Prostate cancer
  • Thyroid cancer

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY END-USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Oncology clinics
  • Diagnostic laboratories
  • Research centres and academic institutes

GLOBAL CARCINOEMBRYONIC ANTIGEN MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Carcinoembryonic Antigen Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Carcinoembryonic Antigen Market Snippet by Gender
    • 2.1.2. Carcinoembryonic Antigen Market Snippet by Application
    • 2.1.3. Carcinoembryonic Antigen Market Snippet by End-user
    • 2.1.4. Carcinoembryonic Antigen Market Snippet by Country
    • 2.1.5. Carcinoembryonic Antigen Market Snippet by Region
  • 2.2. Competitive Insights

3. Carcinoembryonic Antigen Key Market Trends

  • 3.1. Carcinoembryonic Antigen Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Carcinoembryonic Antigen Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Carcinoembryonic Antigen Market Opportunities
  • 3.4. Carcinoembryonic Antigen Market Future Trends

4. Carcinoembryonic Antigen Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Carcinoembryonic Antigen Market: COVID-19 Impact Analysis

  • 5.1. Pre-COVID-19 Impact Analysis
  • 5.2. Post-COVID-19 Impact Analysis
    • 5.2.1. Top Performing Segments
    • 5.2.2. Marginal Growth Segments
    • 5.2.3. Top Looser Segments
    • 5.2.4. Marginal Loss Segments

6. Carcinoembryonic Antigen Market Landscape

  • 6.1. Carcinoembryonic Antigen Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Carcinoembryonic Antigen Market - By Gender

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Gender, 2023 & 2032 (%)
    • 7.1.2. Male
    • 7.1.3. Female

8. Carcinoembryonic Antigen Market - By Application

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Application, 2023 & 2032 (%)
    • 8.1.2. Lung cancer
    • 8.1.3. Gastrointestinal cancer
      • 8.1.3.1. Colorectal cancer
      • 8.1.3.2. Esophageal cancer
      • 8.1.3.3. Liver cancer
      • 8.1.3.4. Pancreatic cancer
      • 8.1.3.5. Stomach cancer
      • 8.1.3.6. Anal cancer
      • 8.1.3.7. Gall bladder cancer
    • 8.1.4. Breast cancer
    • 8.1.5. Ovarian cancer
    • 8.1.6. Prostate cancer
    • 8.1.7. Thyroid cancer

9. Carcinoembryonic Antigen Market - By End-user

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By End-user, 2023 & 2032 (%)
    • 9.1.2. Hospitals
    • 9.1.3. Oncology clinics
    • 9.1.4. Diagnostic laboratories
    • 9.1.5. Research centres and academic institutes

10. Carcinoembryonic Antigen Market- By Geography

  • 10.1. Introduction
    • 10.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 10.2. North America
    • 10.2.1. Overview
    • 10.2.2. Carcinoembryonic Antigen Key Manufacturers in North America
    • 10.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.2.4. North America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.2.5. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.2.6. North America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.7. U.S.
      • 10.2.7.1. Overview
      • 10.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.7.3. U.S. Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.2.7.4. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.7.5. U.S. Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.2.8. Canada
      • 10.2.8.1. Overview
      • 10.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.2.8.3. Canada Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.2.8.4. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.2.8.5. Canada Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.3. Europe
    • 10.3.1. Overview
    • 10.3.2. Carcinoembryonic Antigen Key Manufacturers in Europe
    • 10.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.3.4. Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.3.5. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.3.6. Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.7. Germany
      • 10.3.7.1. Overview
      • 10.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.7.3. Germany Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.7.4. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.7.5. Germany Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.8. France
      • 10.3.8.1. Overview
      • 10.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.8.3. France Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.8.4. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.8.5. France Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.9. Italy
      • 10.3.9.1. Overview
      • 10.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.9.3. Italy Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.9.4. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.9.5. Italy Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.10. Spain
      • 10.3.10.1. Overview
      • 10.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.10.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.10.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.10.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.11. United Kingdom
      • 10.3.11.1. Overview
      • 10.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.11.3. United Kingdom Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.11.4. United Kingdom Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.11.5. United Kingdom Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.12. Russia
      • 10.3.12.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.12.2. Russia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.12.3. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.12.4. Russia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.13. Netherlands
      • 10.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.13.2. Netherlands Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.13.3. Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.13.4. Netherlands Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.14. Sweden
      • 10.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.14.2. Sweden Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.14.3. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.14.4. Sweden Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.15. Poland
      • 10.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.15.2. Poland Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.15.3. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.15.4. Poland Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.3.16. Rest of Europe
      • 10.3.16.1. Overview
      • 10.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.3.16.3. Rest of the Europe Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.3.16.4. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.3.16.5. Rest of the Europe Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.4. Asia Pacific (APAC)
    • 10.4.1. Overview
    • 10.4.2. Carcinoembryonic Antigen Key Manufacturers in Asia Pacific
    • 10.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.4.4. Asia Pacific Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.4.5. Asia Pacific Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.4.6. Asia Pacific Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.7. India
      • 10.4.7.1. Overview
      • 10.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.7.3. India Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.7.4. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.7.5. India Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.8. China
      • 10.4.8.1. Overview
      • 10.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.8.3. China Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.8.4. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.8.5. China Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.9. South Korea
      • 10.4.9.1. Overview
      • 10.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.9.3. South Korea Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.9.4. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.9.5. South Korea Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.10. Japan
      • 10.4.10.1. Overview
      • 10.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.10.3. Japan Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.10.4. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.10.5. Japan Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.11. Australia
      • 10.4.11.1. Overview
      • 10.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.11.3. Australia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.11.4. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.11.5. Australia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.12. Thailand
      • 10.4.12.1. Overview
      • 10.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.12.3. Thailand Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.12.4. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.12.5. Thailand Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.13. Indonesia
      • 10.4.13.1. Overview
      • 10.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.13.3. Indonesia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.13.4. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.13.5. Indonesia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.14. Philippines
      • 10.4.14.1. Overview
      • 10.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.14.3. Philippines Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.14.4. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.14.5. Philippines Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.4.15. Rest of APAC
      • 10.4.15.1. Overview
      • 10.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.4.15.3. Rest of APAC Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.4.15.4. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.4.15.5. Rest of APAC Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.5. Latin America
    • 10.5.1. Overview
    • 10.5.2. Carcinoembryonic Antigen Key Manufacturers in Latin America
    • 10.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.5.4. Latin America Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.5.5. Latin America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.5.6. Latin America Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.7. Brazil
      • 10.5.7.1. Overview
      • 10.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.7.3. Brazil Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.7.4. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.7.5. Brazil Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.8. Mexico
      • 10.5.8.1. Overview
      • 10.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.8.3. Mexico Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.8.4. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.8.5. Mexico Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.9. Argentina
      • 10.5.9.1. Overview
      • 10.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.9.3. Argentina Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.9.4. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.9.5. Argentina Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.10. Colombia
      • 10.5.10.1. Overview
      • 10.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.10.3. Colombia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.10.4. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.10.5. Colombia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.5.11. Rest of LATAM
      • 10.5.11.1. Overview
      • 10.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.5.11.3. Rest of LATAM Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.5.11.4. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.5.11.5. Rest of LATAM Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
  • 10.6. Middle East and Africa
    • 10.6.1. Overview
    • 10.6.2. Carcinoembryonic Antigen Key Manufacturers in Middle East and Africa
    • 10.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 10.6.4. Middle East and Africa Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
    • 10.6.5. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 10.6.6. Middle East and Africa Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.7. Saudi Arabia
      • 10.6.7.1. Overview
      • 10.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.7.3. Saudi Arabia Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.7.4. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.7.5. Saudi Arabia Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.8. United Arab Emirates
      • 10.6.8.1. Overview
      • 10.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.8.3. United Arab Emirates Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.8.4. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.8.5. United Arab Emirates Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.9. Israel
      • 10.6.9.1. Overview
      • 10.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.9.3. Israel Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.9.4. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.9.5. Israel Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.10. Turkey
      • 10.6.10.1. Overview
      • 10.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.10.3. Turkey Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.10.4. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.10.5. Turkey Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.11. Algeria
      • 10.6.11.1. Overview
      • 10.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.11.3. Algeria Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.11.4. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.11.5. Algeria Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.12. Egypt
      • 10.6.12.1. Overview
      • 10.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.12.3. Egypt Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.12.4. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.12.5. Egypt Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)
    • 10.6.13. Rest of MEA
      • 10.6.13.1. Overview
      • 10.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 10.6.13.3. Rest of MEA Market Size and Forecast, By Gender, 2019 - 2032 (US$ Million)
      • 10.6.13.4. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 10.6.13.5. Rest of MEA Market Size and Forecast, By End-user, 2019 - 2032 (US$ Million)

11. Key Vendor Analysis- Carcinoembryonic Antigen Industry

  • 11.1. Competitive Dashboard
  • 11.2. Company Profiles
    • 11.2.1. Boster Biological Technology
    • 11.2.2. Abcam Limited
    • 11.2.3. Creative Diagnostics
    • 11.2.4. Aviva Systems Biology Corporation
    • 11.2.5. AdvaCare Pharma
    • 11.2.6. F. Hoffmann-La Roche Ltd.
    • 11.2.7. Thermo Fisher Scientific Inc.
    • 11.2.8. Omega Diagnostics Ltd.
    • 11.2.9. Medix Biochemica
    • 11.2.10. RayBiotech, Inc.
    • 11.2.11. Diazyme Laboratories Inc.
    • 11.2.12. Quest Diagnostics Incorporated
    • 11.2.13. Others

12. 360 Degree Analyst View

13. Appendix

  • 13.1. Research Methodology
  • 13.2. References
  • 13.3. Abbreviations
  • 13.4. Disclaimer
  • 13.5. Contact Us